Email
Print-Friendly
SubscribeHIV Care Today
By Paul E. Sax, M.D.
June 2, 2012
From NIAID, an important clinical trial has been stopped early.
By Paul E. Sax, M.D.
May 25, 2012
As I'm sure you've heard from your patients -- as I did -- lamivudine (3TC) is now available generically.
Now comes news of the release of several generic formulations of nevirapine (NVP), an effective but always somewhat overshadowed medication. Since its approval way back when in 1996, there has always been a solid reason to pick something else.
By Paul E. Sax, M.D.
May 10, 2012
As I've mentioned before, I have no doubt whatsoever that TDF/FTC works for PrEP, provided the person actually takes the med. And while it's not yet approved for this indication, nothing has stopped clinicians from prescribing it already. There's even a CDC "Guidance" on the practice that's now over a year old. Remember, we give TDF/FTC all the time for post-exposure prophylaxis.
By Paul E. Sax, M.D.
April 30, 2012
I'm currently on the inpatient consult service and just saw a guy who fits the typical profile of many hospitalized HIV patients in 2012:
By Paul E. Sax, M.D.
April 23, 2012
The excitement about "treatment as prevention," and the results of Study 052, have led to many patients asking the question (if not in these words, than using others with a less medical slant), "So if I'm on treatment and doing well, just what is the risk of my transmitting HIV to others?"
By Paul E. Sax, M.D.
April 10, 2012
Over in Journal Watch AIDS Clinical Care, Abbie Zuger has written a fascinating perspective on the recent enthusiasm for universal HIV treatment.
Her take? Let's just say she doesn't share the enthusiasm of public health officials and members of guidelines committees. Well, that's a huge understatement.
By Paul E. Sax, M.D.
March 27, 2012
From the key "What's New in the Guidelines" section of today's Department of Health and Human Services update:
ART is recommended for all HIV-infected individuals. The strength of this recommendation varies on the basis of pretreatment CD4 cell count.
By David Fawcett, Ph.D., L.C.S.W.
March 26, 2012
Several attendees drove fifteen hours from St. Louis. Others came by caravan from Atlanta. In the hotel lobby there were happy reunions of friends who hadn't seen each other since last year. Overall nearly four hundred and fifty people made their way from 22 states to the white sandy beaches of the Florida panhandle in early March. It was spring break, but their purpose was much more a matter of life and death. They were gathering for Positive Living 15, the largest conference in the nation specifically for people living with HIV.
By Paul Sax, M.D.
March 22, 2012
Screening for anal cancer in men who have sex with men (MSM) -- with pap smears, high resolution anoscopy, with whatever test -- is quite the quagmire.
By Paul Sax, M.D.
March 15, 2012
Some highly subjective highlights -- a Really Rapid Review™ -- from this year's Number One Greatest Super Scientific HIV Conference, the 19th Conference on Retroviruses and Opportunistic Infections (CROI), which ended last week in Seattle:
Get email notifications every time HIV Care Today is updated.
This article was provided by TheBodyPRO.com. HIV Care Today is a multi-author blog featuring people on the frontlines of HIV treatment, prevention and patient/client care. This blog serves as a platform for these health care professionals to discuss the everyday challenges of their jobs, recent developments in their fields and issues relevant to the evolution of HIV/AIDS care.
Subscribe to This Blog:
 | By RSS  |
 | |
Bloggers and Contributors:
- David Fawcett, Ph.D., L.C.S.W.
- Lisa Fitzpatrick, M.D., M.P.H.
- Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
- Paul E. Sax, M.D.
- Nelson Vergel, B.S.Ch.E., M.B.A.
Recent Posts:
May 6, 2013 - MyHIVclinic.org: Rethinking How We Learn to Practice HIV Medicine
May 2, 2013 - How to Interpret Medical Breakthroughs in the Mainstream Media
April 30, 2013 - Lost and Found: Helping Patients Develop Emotional Resilience: A Blog Entry by David Fawcett, Ph.D., L.C.S.W.
April 29, 2013 - Data Safety Monitoring Board Closes HIV Vaccine Study -- the End of Adenovirus as a Vaccine Vector?
A Brief Disclaimer:
The opinions expressed by TheBodyPRO.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBodyPRO.com itself.
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
